Sec Form 4 Filing - Coll Crespo Blas @ Structure Therapeutics Inc. - 2025-03-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Coll Crespo Blas 2. Issuer Name and Ticker or Trading Symbol Structure Therapeutics Inc. [ GPCR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CHIEF MEDICAL OFFICER (Last) (First) (Middle) C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900 3. Date of Earliest Transaction (MM/DD/YY) 03/01/2025 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares ( 1 ) 03/01/2025 F 1,233 ( 2 ) D $ 7.9166 218,355 D Ordinary Shares ( 1 ) 07/01/2025 A( 3 ) 7,992 A $ 0 226,347 D Ordinary Shares ( 1 ) 07/01/2025 F 1,434 ( 2 ) D $ 6.8366 224,913 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares American Depositary Shares ( 4 ) 05/21/2025 A( 5 ) V 429 ( 4 ) ( 4 ) Ordinary Shares ( 1 ) 1,287 $ 0 1,157 D American Depositary Shares ( 4 ) ( 4 ) ( 4 ) Ordinary Shares ( 1 ) 3,000 1,000 I By spouse

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Coll Crespo Blas C/O STRUCTURE THERAPEUTICS INC. 601 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA94080 CHIEF MEDICAL OFFICER Signatures /s/ Jun Yoon, Attorney-in-Fact 07/03/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. ( 2 )Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. ( 3 )On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date. ( 4 )Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. ( 5 )Voluntary reporting of the acquisition of 429 ADSs by the Reporting Person on May 21, 2025 pursuant to the Issuer's Employee Share Purchase Plan.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.